Immune checkpoint inhibitors (ICI) have revolutionized the field of cancer treatment. ICI can enhance the antitumor effect, however, it can also induce excessive activation of the immune response, leading to normal tissue damage and trigger immune-related adverse events. In the immunotherapy of non-small cell lung cancer (NSCLC), ICI-related pneumonia (CIP) is rare but has extremely high mortality, it occurs from 7% to 13%. Moreover, with the increased use of ICI in NSCLC, identifying high-risk factors and underlying mechanisms for CIP are key points in preventing and monitoring adverse events. This article reviewed the research progress in the pathogenesis, risk factors, and predictive factors of CIP, in order to improve clinical understanding of the disease and provide reference for patient safety management.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |